Ubs Group Ag Lava Therapeutics Nv Transaction History
Ubs Group Ag
- $527 Billion
- Q4 2024
A detailed history of Ubs Group Ag transactions in Lava Therapeutics Nv stock. As of the latest transaction made, Ubs Group Ag holds 18,431 shares of LVTX stock, worth $17,325. This represents 0.0% of its overall portfolio holdings.
Number of Shares
18,431
Previous 1,072
1619.31%
Holding current value
$17,325
Previous $1,000
1700.0%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding LVTX
# of Institutions
27Shares Held
3.45MCall Options Held
7KPut Options Held
500-
Redmile Group, LLC San Francisco, CA2.07MShares$1.95 Million0.16% of portfolio
-
Bruce & Co., Inc. Chicago, IL772KShares$725,5610.33% of portfolio
-
Sphera Funds Management Ltd. Tel Aviv, L3126KShares$118,7480.03% of portfolio
-
Pathway Financial Advisors LLC103KShares$96,3500.02% of portfolio
-
Pnc Financial Services Group, Inc. Pittsburgh, PA65KShares$61,1000.0% of portfolio
About LAVA Therapeutics NV
- Ticker LVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,797,700
- Market Cap $24.2M
- Description
- LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer...